Inhibiting miR-1 attenuates pulmonary arterial hypertension in rats

YUN LIU1*, YONG LI2*, JINHAI LI1, XIANGRONG ZUO1, QUAN CAO1, WEIPING XIE3 and HONG WANG3

Departments of 1Intensive Care Medicine, 2Cardiology and 3Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China

Received April 11, 2020; Accepted January 27, 2021

DOI: 10.3892/mmr.2021.11922

Abstract. MicroRNAs (miRs) are reported to serve key roles in pulmonary arterial hypertension (PAH). miR-1 has been found in cardiovascular diseases. The present study aimed to determine whether the knockdown of miR-1 could inhibit right ventricle (RV) remodeling and thereby control PAH in model rats. PAH model rats were established by exposing rats to hypoxia, while cardiac fibroblasts (CFs) obtained from PAH model rats were treated with hypoxia to establish an in vitro model, and RV remodeling was evaluated by Masson staining and the levels of collagen I, collagen III, α-smooth muscle actin (α-SMA) and connective tissue growth factor (CTGF) evaluated by western blotting or reverse transcription-quantitative PCR. The results revealed that the expression levels of miR-1 were upregulated in the RV of PAH model rats induced with hypoxia and in the CFs treated with hypoxia. The mean pulmonary arterial pressure, RV systolic pressure, RV/ (left ventricle + interventricular septum) and RV/tibia length were increased in PAH rats; however, the increases in all parameters were subsequently reversed by transfection with a miR-1 antagomiR in PAH model rats. The transfection with the miR-1 antagomiR inhibited the development of RV fibrosis and downregulated the mRNA expression levels of collagen I, collagen III, α-SMA and CTGF in the RV tissue of PAH model rats. The upregulation of collagen I, collagen III, α-SMA and CTGF expression levels in hypoxia-treated CFs was also subsequently reversed by miR-1 antagomiR transfection. The expression levels of collagen I, collagen III, α-SMA and CTGF were also upregulated in the CFs obtained from PAH model rats, and these increases were attenuated by miR-1 antagomiR transfection. The expression levels of phosphorylated (p)-PI3K and p-AKT were also upregulated in hypoxia-treated CFs, and these increases were also inhibited by transfection with miR-1 antagomiR. In conclusion, these results indicated that inhibiting miR-1 may attenuate RV hypertrophy and fibrosis in PAH model rats, a mechanism that may involve the PI3K/AKT signaling pathway.

Introduction

Pulmonary arterial hypertension (PAH) is a pathological condition that occurs in the cardiovascular system (1). In PAH, pulmonary vascular resistance and pulmonary artery pressure increase, ultimately resulting in right heart failure and even death (2,3). Maladaptive processes, such as fibrosis, can damage or even collapse the function of the right ventricle (RV) (4).

MicroRNAs (miRNAs/miRs) are a group of small endogenous non-coding RNAs that can negatively regulate target gene expression post-transcriptionally, mainly through mRNA degradation or translational inhibition (5-8). Alterations in the expression levels of miRNAs have been associated with a number of pathological disease processes, such as cardiovascular diseases. For this reason, circulating miRNAs have been hypothesized to be potential biomarkers or therapeutic targets for several types of disease, such as miR-29 in atrial fibrillation and miR-133a in myocardial infarction (9,10). In fact, several miRNAs, including miR-143, miR-124, miR-140-5p and miR-135a, have been reported to be dysregulated in PAH animal models or patients with PAH (11-14). Previous studies have revealed that miR-1 was involved in the pathogenesis of left heart failure and left ventricle (LV) fibrosis (15,16). Dysregulated miR-1 biogenesis was previously associated with heart failure in aged rats, especially aged hypertensive rats (17). In addition, the expression levels of miR-1 were upregulated in lungs from an experimental model of PAH and in the plasma from patients with PAH, and miR-1 induced endothelial dysfunction, suggesting a pathophysiological role for miR-1 in PAH (18). In a previous study, the transfection with the miR1 antagomiR downregulated the expression levels of TGF-β and collagen hyperplasia in myocardial infarction model mice (19). However, to the best of our knowledge, whether miR-1 may be involved in the regulation of PAH remains unknown.

Key words: microRNA-1, pulmonary hypertension, hypoxia, fibrosis, cardiac fibroblasts

*Correspondence to: Dr Hong Wang, Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu 210029, P.R. China
E-mail: hong_wangnj@163.com

*Contributed equally
The PI3K/AKT signaling pathway was discovered to be involved in the regulation of cardiac fibrosis (20). A previous study revealed that miR-132 activated the PI3K/AKT signaling pathway by downregulating PTEN expression levels, thus inhibiting apoptosis and facilitating cardiomyocyte proliferation and cardiac fibrosis in dilated cardiomyopathy model rats (21). However, whether the PI3K/AKT signaling pathway may be involved in the regulatory effects of miR-1 on cardiac fibrosis in PAH remains unclear.

The present study aimed to determine whether the knockdown of miR-1 could counter PAH through attenuating RV fibrosis in PAH model rats, and whether the PI3K/AKT signaling pathway may be involved in the key roles of miR-1 in regulating fibrosis in CFs.

**Materials and methods**

**Animal studies.** Experiments were performed using 78 5–6 weeks-old male Sprague-Dawley (SD) rats (weight, 180–200 g; Beijing Vital River Laboratory Animal Technology Co., Ltd.). All procedures were approved by the Experimental Animal Care and Use Committee of Nanjing Medical University (Nanjing, China; approval no. 17041015), and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85–23, revised 1996) (22). The rats were kept in a temperature (22±1˚C) and humidity (40–60%)‑controlled room under a 12‑h light‑dark cycle with free access to standard chow and tap water. The experiments were performed at the Animal Core Facility of Nanjing Medical University.

**Establishment of hypoxia rat model and grouping.** The establishment of the hypoxic condition was performed as previously described (23). Briefly, SD rats were divided into 2 groups: i) Normoxia group (n=8), in which rats received normoxia (21% O2) for 4 weeks; and ii) hypoxia group (n=13), in which rats received hypoxia (10% O2) for 24 h. The hypoxic atmosphere was 95% N2, 5% CO2, and 1% streptomycin, and maintained at 37˚C in a humidified atmosphere with 5% CO2 and 95% O2. CFs from the second passage were used for the subsequent experiments.

**CF transfection with miR-1 antagoniR.** Negative control (NC) antagoniR and miR-1 antagoniR were synthesized by Guangzhou RiboBio Co., Ltd. CFs were seeded into 12-well plates at a density of 5x10^4 cells/ml and transfected with 100 nM NC antagoniR or miR-1 antagoniR using Lipofectamine 3,000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) for 6 h. Subsequently, the CFs were treated with hypoxic or normoxic conditions for 24 h. The sequences of the oligonucleotides were as follows: NC antagoniR, 5'-CAGUACUUUGUGUAGUCAA-3'; and miR-1 antagoniR, 5'-UAUAUCUCAUUUGUAUCAA-3'.

**Masson's trichrome staining.** The rats were sacrificed by cervical dislocation following anesthesia with 3.5% isoflurane induction and 2% isoflurane maintenance, and the hearts were removed. The RV tissues were fixed with 4% paraformaldehyde at 4˚C for 24 h, and embedded in paraffin. Cardiac sections (5-µm) were subsequently analyzed using Masson's trichrome staining (Nanjing Biochannel Biotechnology Co., Ltd.) to measure the fibrosis of cardiomyocytes. Briefly, sections were incubated in celestine blue solution for 5 min, washed with
H$_2$O; incubated in hemalun solution for 5 min, in H$_2$O for 10 min, in 0.5% fuchsine acid and 1.5% Ponceau xylidine for 5 min, washed with H$_2$O; incubated in 1% phosphomolybdic acid for 10 min, in 2.5% aniline blue solution for 5 min, washed with H$_2$O; incubated in 1% acetic acid for 1 min, and then briefly in an ascending isopropanol series followed by xylol. All the operations were performed at room temperature. Then 3‑5 randomly selected fields of view were selected from each of three sections from one rat and observed under a light microscope (magnification, x200; Carl Zeiss AG). Images were analyzed using Image‑Pro Plus software (version 6.0; Media Cybernetics, Inc.).

**Reverse transcription‑quantitative PCR (RT‑qPCR).** Total RNA was extracted from RV tissues or CFs using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed into cDNA using random primers in a total volume of 10 µl and PrimeScript™ RT Master mix (Takara Biotechnology Co., Ltd.), according to the manufacturer's protocol, at 37˚C for 15 min and 85˚C for 5 sec. cDNA was stored at -70˚C prior to use. qPCR of miR‑1, collagen I, collagen III, α‑smooth muscle actin (SMA) and connective tissue growth factor (CTGF) expression levels were determined using SYBR Green I fluorescence (Invitrogen; Thermo Fisher Scientific, Inc). All samples were amplified in triplicate in 96‑well plates using the following thermocycling conditions: Initial denaturation at 95˚C for 10 min; followed by 40 cycles at 95˚C for 10 sec and 60˚C for 1 min. GAPDH or U6 were used as the internal controls for mRNA and miRNA, respectively. Relative expression levels were quantified using the 2$^{−ΔΔCq}$ method (26‑29). The primers used for the qPCR are shown in Table I.

**Western blotting.** Total protein was extracted from CFs using RIPA lysis buffer (BioChannel Biotechnology Co., Ltd.) and homogenized. Debris that had not been homogenized was removed, and the supernatant was obtained through centrifugation at 12,000 x g for 10 min at 4˚C. Total protein was quantified by BCA (Beyotime Institute of Biotechnology), and ~50 µg protein was separated via 8% SDS‑PAGE. The separated proteins were subsequently transferred onto PVDF membranes and blocked by 5% skimmed milk powder at room temperature for 1 h. The membranes were then incubated with the following primary antibodies at 4˚C overnight: Anti‑collagen I (1:2,000; cat. no. ab34710; Abcam), anti‑collagen III (1:5,000; cat. no. ab7778; Abcam), anti‑α‑SMA (1:2,000; cat. no. ab32575; Abcam), anti‑CTGF (1:1,000; cat. no. ab6992; Abcam), anti‑PI3K (1:1,000; cat. no. 4249; Cell Signaling Technology, Inc.), anti‑phosphorylated (p)‑PI3K (1:1,000; cat. no. 17366; Cell Signaling Technology, Inc.), anti‑AKT (1:1,000; cat. no. 4691; Cell Signaling Technology, Inc.), anti‑p‑AKT (1:2,000; cat. no. 4060; Cell Signaling Technology, Inc.) and anti‑GAPDH (1:10,000, cat. no. ab181602; Abcam). The horseradish peroxidase‑conjugated goat anti‑rabbit secondary antibody (1:10,000, cat. no. ab7090; Abcam) was added and incubated at room temperature for 1 h. ECL kit (Beyotime Institute of Biotechnology) was used to visualize the proteins. Densitometric analysis was performed using Image‑Pro Plus software (version 6.0; Media Cybernetics, Inc.).

**Statistical analysis.** Statistical analysis was performed using GraphPad Prism 6.0 software (GraphPad Software, Inc.). Data are presented as the mean ± SEM. Statistical differences between two groups were determined using a unpaired Student's t‑test, while statistical differences between multiple groups were determined using a one‑way ANOVA followed by a Bonferroni's post hoc test. A total of 3 experimental repeats were performed. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Hypoxia induces PAH in rats.** PAH was successfully induced by hypoxia in the rat model, as evidenced by an increased mPAP (Fig. 1A) and RVSP (Fig. 1B) compared with rats...
exposed to normoxia. Hypoxia exposure also significantly increased RV/(LV + S) (Fig. 1C) and RV/TL (Fig. 1D) in the rats compared with normoxia exposure.

Expression levels of miR-1. The expression levels of miR-1 were significantly increased in the RV of PAH model rats exposed to hypoxia compared with rats exposed to normoxia (Fig. 2A). To determine the effect of hypoxia on the expression levels of miR-1 in CFs, three gradient O₂ concentrations were used. The expression levels of miR-1 in CFs were sequentially upregulated as the O₂ concentration gradually decreased compared with the normoxia group; the exposure to 5 or 3% O₂ significantly upregulated miR-1 expression levels compared with exposure to normoxia. Notably, exposure to N₂ was more powerful in upregulating miR-1 expression levels compared with 5% O₂ exposure (Fig. 2B). 3% O₂ was selected for use in the following experiments. The expression levels of miR-1 were significantly upregulated following 24 h, but not
12 h of hypoxia exposure compared with CFs not exposed to hypoxia; however, this upregulation was not further enhanced after 48 h of exposure compared with 24 h (Fig. 2C). Thus, 24 h hypoxia stimulation was used in the following *in vitro* experiments. miR-1 antagomiR significantly downregulated the expression levels of miR-1 in the RV of rats compared with the NC antagomiR (Fig. 2D). Furthermore, the expression levels of miR-1 were significantly downregulated in CFs transfected with miR-1 antagomiR compared with NC antagomiR (Fig. 2E).

**Effects of miR-1 antagomiR on PAH.** Hypoxia-induced an increase in mPAP, which was inhibited by miR-1 antagomiR (Fig. 3A). RVSP was increased in the rats treated with hypoxia, which was reversed by miR antagomiR (Fig. 3B). The increase of RV/(LV+S) of rats induced by hypoxia was alleviated by miR antagomiR administration (Fig. 3C). RV/TL was elevated in the rats treated with hypoxia, and this increase was attenuated by administration of miR-1 antagomiR (Fig. 3D).

**Effects of miR-1 antagomiR on fibrosis in PAH model rats.** According to the results of Masson's trichrome staining, the RV fibrosis was increased following hypoxia treatment; this increase was subsequently partially reversed following miR-1 antagomiR transfection (Fig. 4A). The mRNA expression levels of collagen I, collagen III, α-SMA and CTGF in the RV of PAH model rats exposed to hypoxia were significantly upregulated; these increases were partially inhibited following miR-1 antagomiR transfection (Fig. 4B).

**Effects of miR-1 antagomiR on fibrosis in CFs.** Following 3% O2 exposure (hypoxia), the mRNA expression levels of collagen I, collagen III, α-SMA and CTGF were significantly upregulated in CFs compared with the normoxia group, which were all subsequently attenuated following miR-1 antagomiR transfection (Fig. 5A). The protein expression levels of collagen I, collagen III, α-SMA and CTGF were also significantly upregulated in CFs exposed to hypoxia compared with the normoxia group, and these increases were partially inhibited by miR-1 antagomiR transfection (Fig. 5B).

**Effects of miR-1 antagomiR on fibrosis in PAH model rats.** The expression levels of collagen I in CFs isolated from PAH model rats (PCFs) were significantly upregulated compared with CFs isolated from normoxia rats (NCFs), while the subsequent transfection with miR-1 antagomiR inhibited this upregulation (Fig. 6). Collagen III expression levels were also significantly upregulated in PAFs compared with NCFs, and were also attenuated by miR-1 antagomiR transfection. Similarly, the expression levels of α-SMA and CTGF in PCFs treated with NC antagomiR were upregulated compared with in NCFs treated with NC antagomiR, and the increases in α-SMA and CTGF expression levels in PCFs were inhibited by miR-1 antagomiR transfection.
Involvement of the PI3K/AKT signaling pathway in PAH. The expression levels of p-PI3K/PI3K were upregulated in CFs exposed to hypoxia, and this increase was subsequently inhibited by miR-1 antagomiR transfection. Furthermore, the expression levels of p-AKT were also upregulated in CFs exposed to hypoxia compared with the normoxia CFs, and this increase was partially reversed following miR-1 antagomiR transfection (Fig. 7).

Discussion

Hypoxia plays an initiating role in the pathogenesis of PAH. Numerous miRs have been found to be dysregulated in the lung and heart of PAH model rats under chronic hypoxic and monocrotaline (MCT) environments (30-32). The results of the present study demonstrated that knocking down miR-1 expression attenuated PAH and RV fibrosis in PAH model rats, a process that was suggested to involve the PI3K/AKT signaling pathway.

PAH is refractory and devastating; however, there are currently no effective treatments available. miRNAs have emerged as novel targets for PAH treatment and numerous miRNAs play a role in the development of PAH(33). For example, one previous study reported that miR-204 expression levels were downregulated in lung tissue from humans, mice and rats.
with PAH, and knocking down miR-204 expression increased the proliferation and decreased the apoptosis of pulmonary artery smooth muscle cells in patients with PAH (34). The expression levels of miRNAs show model-derived differences.
Figure 6. miR-1 antagomiR attenuates the fibrosis in CFs isolated from PAH model rats. The expression levels of collagen I, collagen III, α-SMA and CTGF in PCFs treated with NC antagomiR were upregulated compared with NCFs treated with NC antagomiR. These increases were subsequently inhibited by transfection with the miR-1 antagomiR. The results are presented as the mean ± SEM. *P<0.05 vs. normoxia + NC antagomiR; #P<0.05 vs. hypoxia + NC antagomiR. miR, microRNA; CFs, cardiac fibroblasts; PAH, pulmonary arterial hypertension; SMA, smooth muscle actin; CTGF, connective tissue growth factor; NC, negative control; PCFs, CFs isolated from PAH model rats; NCFs, CFs isolated from normoxia rats.

Figure 7. Enhancement of PI3K/AKT signaling pathway is inhibited by miR-1 antagomiR. (A) Representative western blotting of p-PI3K, PI3K, p-AKT and AKT expression levels. Expression levels of (B) p-PI3K/PI3K and (C) p-AKT/AKT were upregulated in CFs induced by hypoxia, and this increase was reversed by transfection with miR-1 antagomiR. The results are presented as the mean ± SEM. *P<0.05 vs. normoxia + NC antagomiR; #P<0.05 vs. hypoxia + NC antagomiR. miR, microRNA; p-, phosphorylated; NC, negative control; CFs, cardiac fibroblasts.
For example, MCT and hypoxia induced consistent changes in miR-30c and miR-451, yet regulated miR-22 and miR-21 differently, suggesting that hypoxia- and MCT-induced PAH share some common elements relating to miRs regulation and differential regulation on miRs (31). The results of the present study revealed that the expression levels of miR-1 in the RV were upregulated in rats with hypoxia-induced PAH. In PAH model rats, mPAP and RVSP were also increased, while knocking down miR-1 expression with an antagonomiR reversed these increases in PAH model rats. These results suggested that the expression levels of miR-1 may be dysregulated in the RV of PAH model rats, and that knocking down miR-1 expression may significantly attenuate PAH.

PAH exerts significant pressure on the RV, usually resulting in RV remodeling (35). Pathological hypertrophy is a feature of RV remodeling (36). Restoring the expression of miR-223 in the lungs of rats with MCT-induced PAH provided beneficial effects on RV hypertrophy and vascular remodeling in a previous study (37). In the present study, RV hypertrophy was increased in PAH model rats exposed to hypoxia, as indicated by the increases in the RV/(LV+S) and RV/TL. Transfection with the miR-1 antagonomiR reversed these increases, indicating that knocking down miR-1 may control RV hypertrophy in PAH model rats.

RV fibrosis is another feature of PAH-induced RV remodeling, which is consistently observed in patients with PAH (38,39) and animal models (40,41). The present study found that the expression levels of collagen I, collagen III, α-SMA and CTGF were upregulated in the RV of PAH model rats exposed to normoxia, and these increases were inhibited following miR-1 antagonomiR transfection. miR-1 antagonomiR also attenuated the increases in the expression levels of collagen I, collagen III, α-SMA and CTGF in CFs stimulated with hypoxia. Similarly, the expression levels of collagen I, collagen III, α-SMA and CTGF in CFs from PAH model rats were upregulated, which were downregulated by miR-1 antagonomiR transfection. These results suggested that knocking down miR-1 expression may reverse the fibrosis of RV in PAH model rats.

The PI3K/AKT signaling pathway plays a key role in the fibrosis of the heart (42). Cardiac fibroblast proliferation and migration following myocardial infarction were found to be regulated by the PTEN/PI3K/AKT/mTOR signaling pathway (20). PI3K/AKT signaling was also demonstrated to be necessary for hypoxia-induced CF differentiation and extracellular matrix synthesis (43). The results of the present study reported that the expression levels of p-PI3K were upregulated in CFs exposed with hypoxia, while the transfection with the miR-1 antagonomiR partially inhibited this increase. Furthermore, the expression levels of p-AKT were also upregulated in CFs exposed with hypoxia, and these expression levels were also reversed following miR-1 antagonomiR transfection. These results indicated that the PI3K/AKT signaling pathway may be involved in the regulation of miR-1 in the cardiac fibrosis of PAH.

In conclusion, the findings of the present study suggested that knocking down miR-1 expression may control PAH, and attenuate RV hypertrophy and fibrosis induced by PAH. The results indicated that these effects may occur via a regulatory mechanism that may involve the PI3K/AKT signaling pathway.

Future studies should aim to analyze the expression levels of miR-1 in patients with PAH to determine whether miR-1 expression is dysregulated. The present results suggested that miR-1 may be a potential novel target for the treatment of PAH.

Acknowledgements

Not applicable

Funding

The present study was supported by grants from the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

Yu L and Yo L made substantial contributions to conception and design, and acquisition of data. JL and XZ made substantial contributions to analysis of data. WX and QC made substantial contributions to design, and drafting the manuscript. All authors reviewed the manuscript and revising it. Yu L and HW were responsible for confirming the authenticity of raw data. All authors reviewed and approved the final manuscript.

Ethics approval and consent to participate

All procedures were approved by the Experimental Animal Care and Use Committee of Nanjing Medical University (Nanjing, China; approval no. 17041015), and were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication no. 85-23, revised 1996) (22).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kovacs G, Dumitrescu D, Barner A, Greiner S, Grünig E, Hager A, Köhler T, Kozlik-Feldmann R, Kruck I, Lammers AE, Mereles D, et al: Definition, clinical classification and initial diagnosis of pulmonary hypertension: Updated recommendations from the cologne consensus conference 2018. Int J Cardiol 272S: 11-19, 2018.
2. Lan NSH, Massam BD, Kulkarni SS and Lang CC: Pulmonary arterial hypertension: Pathophysiology and treatment. Diseases 6: 38, 2018.
3. Guiot J, Parzibut G, Weber T, Davin L, Dulgheru R, Lancellotti P, Louis R and Vachiery JL: Pulmonary arterial hypertension. Rev Med Liege 74: 139-45, 2019 (In French).
22. Mohr AM and Mott JL: Overview of microRNA biology. Semin Liver Dis 35: 3-11, 2015.

19. Caruso P, Dunmore BJ, Schlosser K, Schoors S, Dos Santos C, Perez-Iturra C, Lavoie JR, Zhang H, Long L, Flockton AR, et al: Identification of MicroRNA-124 as a major regulator of endothelial cell proliferation in pulmonary arterial hypertension. Circ Res 111: 673-683.e3, 2017.

20. Davenport W, Papadopoulos P, Ordog B, Clauss S, Chen Y, Iwasky S, Voigt N, Qi XY, Sinner MF, Dobrev D, et al: MicroRNA29A: A mechanistic contributer and potential biomarker in atrial fibrillation. Circulation 127: 1466-1475, 1475e1-28, 2013.

21. Eitel I, Adams V, Dieterich K, Dietz M, Allen RM, Guth-Gundel S, Southwood M, Morrell NW, Rothman AM, Arnold ND, Pickworth JA, Iremonger J, Ciuclan L, Yin H, Teng X, Zhang L, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 3551, 2019.

22. Huitinga P, Wiegertjes GF, van Mil WA, de Boer A, de Vries LS, de Koning HH, et al: Targeted inhibition of focal adhesion transduction pathway. J Cell Biochem: Sep 14, 2018 (Epub ahead of print). doi: 10.1002/jcb.27081.

23. Wang Y, Pandey RN, York AJ, Mallela J, Nichols WC, Hu YC, Molkentin JD, Wikenheiser-Brokamp KA and Hegde RS: The EYA3 tyrosine phosphate activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.

24. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 3551, 2019.

25. Lu L, Zhou J, Duan Y, Yu Z, Song Y, Dong Y, Li X, Zhou J, Chen S, Li J, Ge Y, et al: miR-132 rescues cardiac fibrosis and restores heart function. J Clin Invest 126: 2495-2508, 2016.

26. Caruso P, Maclean RR, Khanin R, McClure J, Soon E, Southgate M, MacDonald RA, Greig JA, Robertson KE, Macklin R, et al: Dynamic changes in MicroRNA expression during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 30: 716-723, 2010.

27. Huitinga P, Wiegertjes GF, van Mil WA, de Boer A, de Vries LS, de Koning HH, et al: Targeted inhibition of focal adhesion transduction pathway. J Cell Biochem: Sep 14, 2018 (Epub ahead of print). doi: 10.1002/jcb.27081.

28. Li X, Zhang J, Chen S, Wang Y, Wang S, Chen X, Yang Y, et al: miR-132 rescues cardiac fibrosis and restores heart function. J Clin Invest 126: 2495-2508, 2016.

29. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.

30. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.

31. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.

32. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.

33. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.

34. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.

35. Luo Y, Teng X, Zhang L, Chen J, Liu Z, Chen X, Zhao S, Yang S, Feng J and Yan X: CD146-HIF-lipha hypoxia reprogramming drives vascular remodeling and pulmonary arterial hypertension. Nat Commun 10: 4143, 2019.